Umbilical Cord Blood for Brain Injury Treatment

Umbilical cord blood, once discarded as waste, is now a promising tool for treating traumatic brain injuries (TBI). Each year, over 1.7 million Americans experience TBI, which leads to inflammation, cell death, and long-term disabilities. Current treatments focus on managing symptoms, but cord blood stem cells offer a way to repair damage by reducing inflammation, promoting neuron growth, and aiding recovery.

Key points:

• What is TBI? Brain damage caused by external forces, leading to lasting effects like memory loss, motor issues, and increased risk of conditions like Alzheimer’s.
• Why cord blood? Rich in stem cells, it supports brain repair without ethical concerns or invasive procedures.
• How does it work? Stem cells reduce inflammation, prevent cell death, and encourage new brain cell and blood vessel growth.
• Research results: Studies show reduced inflammation, improved motor skills, and better cognitive recovery in both animals and humans.
• Storage and use: Cord blood is collected after birth, processed, and cryopreserved for future medical needs, including TBI treatment.

This approach shifts the focus from symptom management to repairing brain damage, offering hope for improved recovery outcomes.

How Cord Blood Helps Treat Brain Injuries

Cord blood cells play a crucial role in tackling the secondary phase of traumatic brain injuries (TBI), which involves inflammation and cell death. These stem cells don't just replace damaged brain cells - they trigger the body's natural repair mechanisms. The key lies in paracrine signaling, where the transplanted cells release chemical messengers that guide the brain's own cells to repair themselves. This "secretome" contains growth factors like BDNF, GDNF, and NGF, which help protect neurons from further damage and support the surrounding brain tissue. This process lays the groundwork for tissue repair and improved brain function.

How Stem Cells Repair Brain Tissue

Once administered, cord blood cells navigate to the injury site using chemical signals like Hepatocyte Growth Factor (HGF) and the SDF-1/CXCR4 axis. Upon arrival, they kickstart multiple repair processes simultaneously. For example, they reduce neuroinflammation by lowering levels of harmful cytokines (TNF-α, IL-1β, IL-6) while boosting anti-inflammatory IL-10. They also prevent apoptosis, or programmed cell death, by blocking pathways like NF-κB and significantly reducing apoptosis markers.

"CB cells can induce repair through mechanisms that involve trophic or cell-based paracrine effects or cellular integration and differentiation." - Cytotherapy

Additionally, these cells promote neurogenesis and angiogenesis. They stimulate the brain's own neural stem cells in areas like the subventricular zone and dentate gyrus, encouraging new neuron growth. At the same time, they enhance blood vessel formation, ensuring damaged areas receive the oxygen and nutrients they need for recovery. Together, these actions lead to noticeable improvements in brain function after TBI.

Benefits for TBI Recovery

The repair mechanisms activated by cord blood cells have shown promising results in animal studies. For instance, researchers at the University of South Florida conducted a study in March 2014 using rats with moderate TBI. Seven days after injury, the rats were treated with 4 million viable cord blood cells. Eight weeks later, the treated group displayed reduced neuroinflammation, nearly restored neurogenesis in the dentate gyrus, and significantly improved motor function. Notably, higher doses - up to 10 million cells - produced even greater behavioral improvements, suggesting a dose-dependent effect.

When combined with Granulocyte Colony Stimulating Factor (G-CSF), cord blood therapy demonstrated enhanced effects. This combination led to stronger reductions in inflammation and higher rates of neurogenesis compared to either treatment alone. Specific improvements included better cognitive abilities, improved motor skills, reduced microglial activation, and preserved white matter integrity.

How Exosomes Support Healing

Exosomes, tiny lipid vesicles released by cord blood stem cells, play a critical role in healing. These vesicles carry proteins and microRNAs that aid in repair and can cross the blood-brain barrier with ease, delivering their therapeutic cargo directly to injured brain tissue. This makes them an efficient alternative to whole-cell therapies, with a lower risk of immune rejection or tumor formation.

"HUCMSCs-derived exosomes significantly reduced proinflammatory cytokine expression by suppressing the NF-κB signaling pathway." - Zhen-Wen Zhang et al., Open Life Sciences

Exosomes suppress inflammation by targeting the NF-κB pathway, reduce neuronal cell death, and prevent scarring (gliosis) in the brain. They also restore white matter structure and deliver growth factors like BDNF, which are essential for recovering neurobehavioral function after TBI. The ability of exosomes to provide these benefits without relying on direct cell integration underscores their potential in brain injury treatment.

Research and Clinical Studies on Cord Blood for TBI

Results from Animal Studies

Preclinical research has revealed encouraging results for using cord blood in treating brain injuries. At Henry Ford Health Sciences Center, a team led by Dunyue Lu administered human cord blood intravenously to rats 24 hours after a traumatic brain injury (TBI). By day 28, the donor cells had migrated to the injured areas of the brain, expressed neuronal markers like NeuN and MAP-2, and improved both motor and neurological functions.

"HUCB cells injected IV significantly reduced motor and neurological deficits compared with control groups by day 28 after the treatment." - Dunyue Lu, Department of Neurosurgery, Henry Ford Health Sciences Center

Another study at Kaohsiung Chang Gung Memorial Hospital, led by Kuan-Hung Chen, involved administering 1.2×10⁶ cord-derived mesenchymal stem cells to rats just three hours after injury. The results were striking: by day 28, the treated group showed better neurological function, reduced brain ischemic volume, and had a zero mortality rate, compared to 16.7% mortality in the untreated group. Importantly, no tumor formation was observed.

"Xenogeneic HUCDMSC therapy was safe and it significantly preserved neurological function and brain architecture in rat after TBI." - Kuan-Hung Chen, Department of Neurosurgery, Kaohsiung Chang Gung Memorial Hospital

These animal studies provide a solid foundation for moving forward with human clinical trials.

Human Clinical Trials

Duke University conducted a Phase I trial exploring the use of cord blood therapy for newborn brain injuries. Completed in 2016, the study included 55 infants with hypoxic-ischemic encephalopathy (HIE), a condition similar to TBI. The results were notable: the group receiving autologous umbilical cord blood infusions had a 100% survival rate to hospital discharge, compared to 85% in the control group that only received cooling therapy.

Further research by Cotten CM and colleagues demonstrated even more promising outcomes. Among infants treated with autologous cord blood cells, 74% (13 of 18) had Bayley III scores ≥ 85 at one year, indicating normal cognitive, language, and motor development. In contrast, only 41% (19 of 46) of infants treated with cooling therapy alone achieved similar scores. Another trial by Tsuji et al. administered three doses of volume-reduced autologous cord blood to six newborns with severe birth asphyxia. By 18 months, four of the six infants (66.7%) exhibited normal neurofunctional development.

These findings underscore the potential of cord blood therapy and have spurred further research into optimizing these treatments.

Current Research Efforts

Duke University has taken steps to develop an off-the-shelf product using cord tissue-derived mesenchymal stromal cells, with safety trial enrollment completed in July 2019. This is particularly important since approximately 66% of infants with neonatal brain injuries do not have access to stored cord blood.

Researchers are also investigating ways to enhance the effectiveness of stem cells through genetic engineering. Modifications that increase the production of neurotrophic factors like FGF21, IL-10, and BDNF could improve cell survival and their regenerative capabilities. Additionally, non-invasive delivery methods, such as intranasal administration, are being studied to directly target the central nervous system. As of late 2022, 18 clinical studies registered on clinicaltrials.gov were exploring the use of umbilical cord blood for perinatal brain injuries.

These efforts aim to refine and expand the therapeutic potential of cord blood treatments.

Cord Blood Collection, Storage, and Treatment Process

How Cord Blood is Collected and Processed

Cord blood is collected right after your baby is born, whether through a vaginal delivery or a cesarean section. The process is quick, painless, and completely safe for both mom and baby. Once the umbilical cord is clamped and cut, a healthcare provider uses a needle to draw blood from the umbilical vein - this is done before the placenta and cord are discarded. The entire collection takes just a few minutes.

After collection, the cord blood is processed to isolate and concentrate the different types of stem cells. This involves removing excess volume and red blood cells to ensure the highest quality of stem cells is preserved. Americord Registry uses a specialized method called CryoMaxx™, which is designed to maintain both the quality and quantity of stem cells during processing. Every unit is rigorously tested for infectious diseases and registered to meet strict safety standards. Once processed, the stem cells are cryopreserved to ensure they remain viable for future medical use.

Storage for Future Medical Use

After processing, the stem cells are stored at extremely low temperatures through cryopreservation. This halts their biological aging, allowing them to remain usable for decades. This type of storage ensures families have access to these cells if they’re needed for future treatments. Americord Registry maintains secure facilities to safeguard the stem cells, ensuring their therapeutic potential is preserved over time.

When selecting a cord blood bank, it’s important to confirm that the facility is accredited by organizations like the Foundation for the Accreditation of Cellular Therapies (FACT) or AABB. These accreditations indicate that the facility adheres to high standards for handling and storage.

Using Stored Cord Blood for TBI Treatment

Once stored cord blood is needed for treatment - such as in cases of traumatic brain injury (TBI) - it is retrieved from cryogenic storage, thawed, and prepared for use. For TBI therapy, the stem cells are typically delivered through intravenous (IV) infusion. Once in the bloodstream, the cells naturally travel to damaged areas of the brain, where they help reduce inflammation and promote the growth of new brain cells (neurogenesis). Clinical trials for pediatric brain injuries often use doses ranging from 1 to 5 × 10⁷ nucleated cells per kilogram of body weight.

Timing is also critical. In most cases, the IV infusion is administered within 48 to 72 hours of injury, though benefits have been observed even in chronic stages, months after the injury occurred. For example, a Phase I trial at the University of Texas Health Science Center treated 10 children (ages 5 to 14) with severe TBIs using their own cord blood stem cells. Six months after the treatment, all 10 children showed significant recovery, with 7 of them experiencing only mild or no lingering disabilities.

Americord Registry Cord Blood Banking Services

Americord Registry Features

Americord Registry stands out in cord blood banking by offering advanced features tailored for regenerative treatments, including therapies for traumatic brain injuries (TBI). The facility is AABB accredited, meeting strict standards for processing and storage. This accreditation ensures the stem cell units are handled with the precision required for clinical trials and regenerative medicine applications, such as TBI therapies.

Using its CryoMaxx™ processing, Americord maximizes cell recovery while preserving growth factors essential for treatment. High cell counts are crucial, as studies on TBI recovery have shown better outcomes with higher doses of viable cells. Additionally, Americord safeguards the "secretome", which includes exosomes and neurotrophic factors like BDNF and GDNF - key players in protecting neurons and repairing brain tissue.

The use of 5-compartment storage vials is another standout feature. These vials allow families to access portions of the stored cord blood for multiple treatments over time, rather than using the entire unit at once. This flexibility is especially beneficial for conditions like TBI, where ongoing or repeated infusions may be necessary as treatment protocols evolve.

Available Plans and Pricing

Americord offers five distinct plans to accommodate varying preservation needs:

• Essential Family Plan: Focuses on cord blood banking with CryoMaxx™ processing.
• Advanced Family Plan: Adds cord blood and cord tissue banking to the Essential plan.
• Complete Family Plan: Includes cord blood, cord tissue, and placental tissue banking.
• Ultimate Family Plan: Builds on the Complete plan by adding newborn exosome banking.
• Maximum Family Plan: The most all-encompassing option, covering cord blood, cord tissue, placental tissue, and both newborn and maternal exosome banking.

Pricing depends on the storage duration families choose, with clear pricing structures to help them select a plan that aligns with their medical and financial priorities. Choosing the right plan is an important step in preparing for future TBI treatments and other medical advancements.

Support for Regenerative Medicine

Americord Registry goes beyond storage by actively supporting regenerative medicine through education and research updates. Cord blood stem cells, known for their longer telomeres and greater ability to differentiate, are particularly promising for neurological recovery. The company's advanced preservation techniques align with the latest research and clinical findings.

Americord provides families with resources to better understand stem cell therapy, helping them differentiate between credible clinical research and exaggerated claims. Families can also access consultation services for guidance on collection, storage, and potential medical uses of their stored cord blood. Additionally, Americord keeps families informed about ongoing clinical trials, such as the UTHealth Phase I study, offering insights into how and when stem cell treatments might be applied to brain injuries. This commitment ensures families stay informed and prepared for future medical opportunities.

Conclusion

Umbilical cord blood has shown promise in treating traumatic brain injuries (TBI), offering a valuable tool in proactive healthcare. The stem cells in cord blood are younger and more adaptable than those from adult bone marrow. They can transform into nerve cells, reduce inflammation, and aid in brain tissue repair. For example, a Phase I trial at the University of Texas Health Science Center at Houston revealed that 70% of children with severe TBI achieved mild or no disability six months after receiving treatment with their own stem cells.

Beyond immediate treatment, cord blood banking provides a long-term resource. Stored cord blood remains viable for decades, opening potential applications not just for TBI but also for conditions like cerebral palsy, stroke, and autism. These stem cells play a critical role by secreting growth factors like BDNF and NGF, which protect neurons and support brain repair. They also encourage angiogenesis, helping restore blood flow to damaged areas and reducing inflammation that can worsen brain injuries.

For families considering cord blood banking, early planning is crucial. Discussing this option with healthcare providers at least six weeks before delivery ensures proper collection arrangements. Selecting an AABB-accredited facility ensures the stem cells are processed and stored to meet high clinical standards, preserving their potential for future use in regenerative medicine.

With more than 40,000 cord blood transplants performed globally since 1988 and ongoing clinical trials expanding its applications, cord blood banking represents a forward-thinking step in medical preparedness. Services like those offered by Americord Registry make these advancements accessible, giving families a way to prepare for future medical needs that could significantly impact their child’s health and recovery.

FAQs

Who can use cord blood therapy for a brain injury?

Cord blood therapy is mainly applied to treat brain injuries in infants and children, particularly those caused by trauma or complications around birth. Research indicates that stem cells from cord blood might aid in regenerating nerves, lowering inflammation, and enhancing motor and cognitive abilities. The treatment tends to be most beneficial when given soon after the injury or birth, especially for children who have access to their own stored cord blood.

What are the risks or side effects of cord blood infusions?

Cord blood infusions are widely regarded as safe, particularly when the cord blood is self-donated (autologous). Research indicates that the risk of complications is minimal, largely because the child's own stem cells have a very low chance of triggering immune reactions.

That said, no medical procedure is entirely without risk. Potential concerns include infections, allergic responses, or problems related to the infusion process itself. It's always a good idea to talk with a healthcare provider to get a clear understanding of the possible risks and benefits specific to your situation.

How long can stored cord blood stay usable for treatment?

Stored cord blood has the potential to remain usable for decades. Studies indicate that, when preserved correctly, it can stay viable for over 20 years or even longer. Improvements in storage methods continue to enhance its durability, ensuring it remains a dependable option for future medical treatments.